van Eijk, Maarten http://orcid.org/0000-0001-7246-4857
Vermunt, Marit A. C.
van Werkhoven, Erik
Wilthagen, Erica A.
Huitema, Alwin D. R.
Beijnen, Jos H.
Article History
Received: 6 September 2021
Accepted: 14 January 2022
First Online: 25 January 2022
Declarations
:
: Not applicable
: Not applicable
: Jos Beijnen is a (partātime) employee and shareholder of Modra Pharmaceuticals, and (partly) holds a patent on oral taxane formulations. The current lead clinical program of Modra Pharmaceuticals is based on a weekly oral docetaxel regimen. The other authors declare that they have no conflict of interest.